What Optellum Announced About Australian TGA Clearance for Virtual Nodule Clinic

Optellum said on 26 February 2026 that it had received Therapeutic Goods Administration class IIb approval in Australia for its Virtual Nodule Clinic platform, which it describes as supporting early lung cancer diagnosis through the identification, triage and management of pulmonary nodules. The company says the platform includes its Lung Cancer Prediction AI tool and was already in use in the United States, the European Union and the United Kingdom. On the same page Optellum states that Virtual Nodule Clinic is FDA cleared, CE-MDR marked, TGA approved and UKCA marked. The announcement cites more than 15,000 new lung cancer diagnoses a year in Australia and a five year survival rate of around 27 percent, and carries no quotes.

Why the Optellum Australian Market Entry Matters to Lung Imaging Buyers

Four regulators in four markets is a useful signal for a buyer, because each one reviewed the same software against its own rules, and that is harder to arrange than a long customer list. It is worth knowing that the words are not interchangeable. Australia granted a class IIb approval, the United States issued a clearance, and Europe and the United Kingdom work through marking rather than either. They are different processes with different bars, so a company holding all four has cleared four different hurdles, not the same one four times. What none of them establish is a result. Permission to sell is not proof that the software found a cancer sooner or changed what a clinician did, and this announcement offers no Australian data at all. The real test is whether an Australian hospital buys it and reports what changed.

Where the Optellum Update Comes From

Optellum is the original record behind this update. It tells us what the company published. This brief adds the market context and the method we would use to test the development against other evidence.

Optellum original source.

How We Would Research the Optellum Australian Regulatory Decision

The source gives us the starting point. This is how we would build the next layer of research around it.

  1. We would start by looking up the Australian Register of Therapeutic Goods entry itself, because the register states the approved intended use in a way a press release does not.
  2. Then we would compare the Australian intended use against the United States clearance wording, since the same software can be permitted for a narrower job in one market than in another.
  3. We would watch for the first named Australian hospital using it, because market entry without a customer is a licence rather than a business.